Science
FDA approval took effect without objection 30 days after submission Single- and multiple-dose regimens to be evaluated in 94 participants through April 2027

Ingenia Therapeutics has received approval for its U.S. clinical trial application for IGT-303, a drug candidate for chronic kidney disease.
Ingenia Therapeutics said on the 27th that the U.S. Food and Drug Administration (FDA) had approved its Phase 1/2a clinical trial application for IGT-303. The approval took effect after 30 days without an objection or request for additional information following the application’s submission to the FDA on Sept. 25.
The company will sequentially evaluate single-ascending-dose and multiple-ascending-dose regimens in a total of 94 participants, including healthy volunteers and patients with chronic kidney disease, at four U.S. sites. The target date for completing the trial is April 30, 2027.
In typical drug development, Phase 1 and Phase 2a trials are conducted separately. Ingenia Therapeutics, however, adopted a seamless integrated design, evaluating single ascending doses (SAD) in six groups in Part A, followed by multiple ascending doses (MAD) in three groups in Part B. The design is intended to complete the work of both stages within a schedule of just over six months from approval to the expected completion date.
Existing multinational clinical data made this design possible. After starting a Phase 1/2a trial of IGT-303 in Australia in November 2025, Ingenia Therapeutics expanded the trial to New Zealand and South Korea and has proceeded to the patient-focused Phase 2a stage. The company said that accumulating safety data in the Asia-Pacific region enabled it to obtain approval for an integrated trial plan in the United States as well.
The practical goal of the U.S. trial is to obtain early clinical proof of concept (PoC) based on data from U.S. patients. IGT-303 is an antibody therapy that activates the TIE2 receptor on glomerular microvascular endothelial cells to repair damaged vascular barriers and suppress inflammation. In preclinical studies in nonhuman primates, it reduced proteinuria by more than 50%, exceeding the 25% to 40% reduction reported for existing standard treatments.
The company expects that confirming pharmacokinetic data for the subcutaneous (SC) formulation, alongside intravenous (IV) administration, in U.S. patients could strengthen its position in licensing negotiations. Ingenia Therapeutics listed on the KOSDAQ market in August and previously licensed its retinal disease pipeline candidate IGT-427 to a global biopharmaceutical company.
Although an integrated trial design can shorten development time, it also carries the risk that the entire schedule could be halted if serious adverse events emerge during dose escalation. Patients with impaired kidney function may have a reduced ability to excrete drugs compared with healthy volunteers, potentially causing blood drug concentrations to change rapidly. Whether the company can recruit all 94 participants on schedule and demonstrate kidney-protective effects and safety in the U.S. patient population is expected to determine the success of subsequent licensing efforts.

BIOBOOK TEAM
biobookmedia@biobook.co.kr
Novartis’ Cosentyx approved for 11th indication, becoming first treatment for polymyalgia rheumatica

Oral IL-23-targeting psoriasis drug icotrokinra approved in Brazil; one tablet daily

Aribio’s Oral Alzheimer’s Drug Meets Trial Goal in Monotherapy Group, Slowing Progression by 31%

SELLAS Leukemia Vaccine Extends Survival by 9 Months, Meets Phase 3 Endpoint

Korean Drugmakers Race to Develop Obesity Treatments That Preserve Muscle During Weight Loss

Growth pathway identified in ‘difficult-to-treat’ triple-negative breast cancer, raising potential to repurpose existing drugs